Table 1. Summary of these 13 eligible studies.
| Author | Year | Country | No | OC/non-OC | FIGO grades | Reference | Matrix | Test method | Data collection |
|---|---|---|---|---|---|---|---|---|---|
| Kim [22] | 2002 | USA | 251 | 51/200 | NR | NR | Plasma | IBL | Unknown |
| Mor [23] | 2005 | USA | 206 | 100/106 | NR | NR | Serum | Assay Designs | Unknown |
| Nakae [24] | 2006 | Japan | 127 | 32/95 | NR | Pathology | Plasma | IBL | Unknown |
| Meinhold-Heerlein [25] | 2007 | Germany | 149 | 67/67 | 7/2/49/9 | NR | Serum | R&D | Unknown |
| Moore [26] | 2008 | USA | 233 | 67/166 | 13/2/46/6 | Pathology | Serum | IBL | Prospective |
| Visintin [27] | 2008 | USA | 518 | 156/362 | 13/23/74/46 | Clinical, surgical, histologic and pathologic | Serum | Beadlyte | Retrospective |
| Fredriksson [28] | 2008 | USA | 39 | 19/20 | 4/0/10/5 | NR | Plasma | Multiplex PLA | Unknown |
| Vrzalova [29] | 2009 | Czech | 39 | 19/20 | NR | NR | Serum | Beadlyte | Unknown |
| Lu [30] | 2011 | USA | 304 | 151/153 | 11/6/98/35 | NR | Serum | Milliplex MAP | Unknown |
| He [31] | 2012 | Canada | 52 | 37/15 | NR | Pathology | Serum | Milliplex MAP | Unknown |
| Bandiera [32] | 2013 | Italy | 180 | 60/120 | NR | NR | Plasma | IBL | Unknown |
| Moszynski [33] | 2013 | Poland | 114 | 32/82 | NR | Histopathological examination | Serum | R&D | Unknown |
| Milivojevic [34] | 2013 | Serbia | 79 | 48/31 | 12/6/23/7 | Histopathological examination | Plasma | NR | Unknown |
NR: not reported. IBL: Immuno-Biological Laboratories. OC: ovarian cancer. FIGO, International Federation of Gynecology and Obstetrics.